RECURRENT LUNG NON-SMALL CELL CARCINOMA
Clinical trials for RECURRENT LUNG NON-SMALL CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT LUNG NON-SMALL CELL CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT LUNG NON-SMALL CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Custom-Made vaccine targets tough cancers in early trial
⭐️ VACCINE ⭐️ Recruiting nowThis early-phase study is testing a personalized vaccine made from each patient's unique tumor mutations. The goal is to see if it is safe and can help the immune system fight advanced breast cancer, melanoma, and non-small cell lung cancer. About 25 adults whose cancers have spr…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: ⭐️ VACCINE ⭐️
Last updated May 18, 2026 12:04 UTC
-
New pill targets hard-to-treat cancers with KRAS and BRAF mutations
Disease control Recruiting nowThis early-stage study tests an oral drug called S241656 in adults with advanced cancers that have certain gene changes (KRAS, BRAF, or related mutations). The drug is given alone or with other cancer treatments. The goal is to find safe doses and see if the drug shrinks tumors. …
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated May 26, 2026 03:35 UTC
-
New hope for rare lung cancer: drug combo targets tumor growth
Disease control Recruiting nowThis study tests whether adding ramucirumab to tepotinib works better than tepotinib alone for people with a certain type of advanced lung cancer (MET exon 14 skipping). Tepotinib blocks a faulty protein that makes cancer grow, while ramucirumab may cut off the tumor's blood supp…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated May 26, 2026 03:35 UTC
-
New combo therapy aims to boost immune attack on tough lung cancers
Disease control Recruiting nowThis early-phase trial is testing a new drug called PBF-1129 combined with the immunotherapy nivolumab in people with advanced non-small cell lung cancer that has returned or spread. The main goal is to find the safest dose and understand side effects. About 30 adults who have al…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: Dwight Owen • Aim: Disease control
Last updated May 26, 2026 03:31 UTC
-
Engineered immune cells target Hard-to-Treat lung cancer in early trial
Disease control Recruiting nowThis early-phase trial tests a new treatment for people with a specific type of advanced lung cancer (FRa+ NSCLC) that has spread to the lining around the lungs. The therapy uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells, the…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated May 26, 2026 03:30 UTC
-
New hope for Hard-to-Treat lung cancer: targeted pill shows promise
Disease control Recruiting nowThis study tests a pill called osimertinib in people with advanced lung cancer that has a specific genetic change (EGFR exon 20 insertion). The drug works by blocking signals that help cancer cells grow. About 46 participants will take the pill daily to see if it shrinks tumors o…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
New drug duo aims to boost immune attack on lung cancer
Disease control Recruiting nowThis study tests whether adding SX-682 to the immunotherapy drug pembrolizumab helps shrink tumors in people with advanced non-small cell lung cancer that has spread or returned. About 30 adults whose tumors have a certain protein (PD-L1) will receive both drugs. The goal is to s…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
New combo therapy aims to boost immune attack on lung cancer
Disease control Recruiting nowThis early-phase trial tests the safety and best dose of combining two drugs—vismodegib and atezolizumab—in people with advanced non-small cell lung cancer that has returned or spread. Vismodegib blocks certain enzymes that help cancer grow, while atezolizumab helps the immune sy…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: Dwight Owen • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
Could a Triple-Drug combo extend life for advanced lung cancer patients?
Disease control Recruiting nowThis study tests whether adding the immunotherapy drug cemiplimab to the standard two-drug combination (docetaxel and ramucirumab) can help people with advanced or recurrent non-small cell lung cancer live longer. Participants have already tried platinum-based chemotherapy and im…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New drug cocktail aims to shrink Hard-to-Treat lung tumors
Disease control Recruiting nowThis study tests whether combining three targeted drugs (capmatinib, osimertinib, and ramucirumab) works better than two drugs alone for people with advanced non-small cell lung cancer that has specific EGFR and MET gene changes. The drugs block signals that help cancer grow and …
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated May 08, 2026 12:00 UTC
-
Can a simple scan predict lung cancer treatment success?
Knowledge-focused Recruiting nowThis study looks at how PET/CT scans change during chemoimmunotherapy and radiation in people with stage IV non-small cell lung cancer. Researchers want to see if these scan changes can help predict how well the cancer responds to treatment. About 80 participants who have not yet…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: NA • Sponsor: University of Washington • Aim: Knowledge-focused
Last updated May 26, 2026 03:36 UTC
-
New platform aims to predict which cancer treatments will work
Knowledge-focused Recruiting nowThis study collects tissue samples from people with various advanced or early-stage cancers to train a diagnostic platform called Elephas. The goal is to see how accurately it can predict whether a patient will respond to immunotherapy or chemoimmunotherapy. About 324 participant…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated May 26, 2026 03:28 UTC